

March 25, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Entry into Marketing and Distribution Agreement for Biosimilars in EU Territories by CuraTeQ Biologics Private Limited

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd and focused on biosimilars, today announces that it has entered into a marketing and distribution agreement with a leading European healthcare and pharmaceuticals company STADA Arzneimittel AG. Under the terms of the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar. This agreement is expected to expand CuraTeQ's market reach, drive revenue growth, and leverage STADA's established distribution network in EU markets.

This is not a material event as per Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com